IP Library Granted Patent US 9,050,376
Granted Patent B2
US 9,050,376 · App. 14/309,245 · Granted Jun 9, 2015

Conjugates of synthetic TLR agonists and uses therefor

Inventors: Dennis A. Carson (La Jolla, CA); Howard B. Cottam (Escondido, CA); Wolfgang Wrasidlo (La Jolla, CA); Christina C. N. Wu (Escondido, CA); Gregory A. Daniels (San Diego, CA)
Assignee: The Regents of the University of California
A61K47/48815A61K31/52A61K39/085A61K39/39A61K2039/55511C07D487/04A61K39/07C07F9/65616A61K2039/55555
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,050,376
App. No.
14/309,245
Granted
Jun 9, 2015
Kind
B2
Abstract

The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.

Claims (16)

1. A composition comprising a compound of formula A:

or a pharmaceutically acceptable salt thereof, wherein

X 1 is —O—;

R 1 is hydrogen, (C 1 -C 10 )alkyl, or, (C 1 -C 10 )alkyl substituted with (C 1 -C 6 )alkoxy;

X 2 is C(O); and

R 3 is a phosphatidyl ethanolamine comprising two C 14 -C 22 carboxylic acid groups each having one, two, three, or four sites of unsaturation, epoxidation, hydroxylation, or a combination thereof, each at a location of the respective carboxylic acid group carbon chain.

2. The composition of claim 1 wherein X 2 -R 3 is bonded to a carbon atom para to the methylene carbon bonded to the heteroaryl nitrogen atom.

3. The composition of claim 1 , wherein the two carboxylic acid groups of the phosphatidyl ethanolamine of the compound of Formula A are the same.

4. The composition of claim 1 , wherein either or both carboxylic acid groups of the phosphatidyl ethanolamine of the compound of Formula A is a C 17 carboxylic acid group with a site of unsaturation at C8-C9.

5. The composition of claim 1 , wherein either or both carboxylic acid groups of the phosphatidyl ethanolamine of the compound of Formula A is a C 18 carboxylic acid group with a site of unsaturation at C9-C10.

6. The composition of claim 1 , wherein R 1 of the compound of Formula A is a (C 1 -C 10 )alkyl substituted with (C 1 -C 6 )alkoxy.

7. The composition of claim 1 , wherein for the compound of Formula A, R 1 is —(CH 2 ) 2 —OCH 3 .

8. The composition of claim 1 , which further comprises a liposome.

9. A composition comprising an amount of a compound of Formula A of claim 1 effective as an adjuvant.

10. A vaccine comprising an antigen and a compound of Formula A of claim 1 .

11. The composition of claim 1 , wherein the two carboxylic acid groups of phosphatidyl ethanolamine of the compound of Formula A are different.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 10, 2020
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 051769/0135 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2015
From: CARSON, DENNIS A.; COTTAM, HOWARD B.; WRASIDLO, WOLFGANG; WU, CHRISTINA C.N.; DANIELS, GREGORY A.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 035115/0037 →
Continuity (4)
Continuation 13736545 · Jan 8, 2013
Division 12027960 · Feb 7, 2008
Provisional Application 60888699 · Feb 7, 2007
Related Publication 20140302120A1 · Oct 9, 2014